Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

Company Overview - Viking Therapeutics, Inc. (VKTX) closed at $27.05, reflecting a decrease of -1.92% from the previous trading session, underperforming compared to the S&P 500's loss of 0.64% [1] - Over the past month, shares of the company have declined by 15.32%, while the Medical sector gained 1.3% and the S&P 500 increased by 1.91% [1] Earnings Projections - The upcoming earnings release is highly anticipated, with projected EPS at -$0.68, indicating a significant drop of 209.09% compared to the same quarter last year [2] - Full-year Zacks Consensus Estimates forecast earnings of -$2.42 per share and revenue of $0 million, representing year-over-year changes of -139.6% and 0%, respectively [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics indicate the dynamic nature of near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for stocks [4] Zacks Rank Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with 1 stocks historically contributing an average annual return of +25% since 1988 [5] - Currently, Viking Therapeutics holds a Zacks Rank of 4 (Sell), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] Industry Context - Viking Therapeutics operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 99, placing it in the top 41% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]